Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 381 to 390 of 1904

TitleReference numberPublishedLast updated
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesotheliomaTA818
Cefiderocol for treating severe drug-resistant gram-negative bacterial infectionsHTE2
Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infectionsHTE1
Type 1 diabetes in adults: diagnosis and managementNG17
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
SecurAcath for securing percutaneous cathetersMTG34
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitorsTA813

Results per page

  1. 10
  2. 25
  3. 50
  4. All